Biopharmaceutical Manufacturing Using Blow–Fill–Seal Technology - The authors give special consideration factors affecting blow–fill–seal technology. - BioPharm International


Biopharmaceutical Manufacturing Using Blow–Fill–Seal Technology
The authors give special consideration factors affecting blow–fill–seal technology.

BioPharm International
Volume 24, Issue 7, pp. 22-29


BFS steps in biological manufacturing

Figure 2: The blow–fill–seal process in the context of biological manufacturing.
Fill–finish operations of biological drug products, particularly proteins or monoclonal antibodies, usually begin with drug substance (or concentrated bulk) supplied either refrigerated at 2–8 C for temporary storage, or frozen at <–20 C for extended storage. The drug substance is thawed, if necessary, at a defined temperature and process. If the drug substance has a different concentration from the final drug product, a formulation buffer can be added and mixed together with the drug substance in a mixing tank, to reach the target concentration as final drug product. The solution is then transferred into a holding tank through a filter to reduce bioburden level. The holding tank containing formulated product can be used to store the product for an extended period of time to accommodate manufacturing scheduling. These operation steps, including thawing, dilution, mixing, and filtration are typically conducted in a Grade C area. Figure 2 illustrates the process flow.

Most parts of the BFS machine are located in a Grade C room; only the filling cabinet is controlled under a Grade A condition. Time-pressure filling, where a pinch valve is used to control the fill volume, is often used in the filling operation. The flow rate is determined by the pressure applied to the liquid reservoir (or surge tank), and the pinch valve opening time determines the final fill volume. During the filling process, solution sterilization is achieved by sterilizing-grade filters.

The connection of the BFS machine with filling needles, surge tank, and sterilizing filter usually takes place in a Grade C environment. The BFS machine is first assembled and cleaned through clean-in-place (CIP) procedures. It then gets connected to the sterilizing filter, and the entire connection is sterilized under a validated steam-in-place (SIP) cycle, from the filling needle, all the way to the point of connection with the product tank.

Aseptic processing requires contamination control and sterilization of three main aspects: drug-product solution, primary container components, and operation environment. The sterilization method for drug product solution in a BFS process is similar to a conventional fill–finish process, where typical sterilizing grade filters are used. Unlike the component processing steps in the conventional fill–finish process (i.e., washing, depyrogenation, and siliconization of vials, syringes, and stoppers), the primary container is formed in the BFS process, and the molding of plastic resin at elevated temperature provides a container "free" of viable microorganisms and with acceptable endotoxin levels. The ability for a BFS extrusion process to yield product with acceptable quality has been demonstrated by controlled challenges studies, where LDPE granulates were contaminated with characterized levels of bacteria spores and endotoxins, then pressessed through a BFS machine using Tropton Soy Broth and Water for Injection as the filling media (4). Higher fractions of contaminated units were observed with increased challenge level (or amount of spores and endotoxin in the plastic granulates). The above study demonstrated it is critical to establish appropriate acceptance limits for bioburden and endotoxin levels on plastic granulates to assure final product quality.

The overall extrusion and molding process of the BFS operation is conducted in a Grade C area. However, the air shower for the filling shroud of the BFS machine should provide a Grade A condition. European Union guidelines state that, "The condition should comply with the viable and nonviable limits at rest and viable limit only when in operation" (5). There is potential risk for airborne contamination before the mold moves to the filling shroud area, where the air shower maintains a Grade A environment. Recent studies have shown that most of the airborne contamination occurs between the time when the top is cut from molded containers and when they pass under the air shower (6). The microbial and particulate controls are highly equipment and site specific. Therefore, a media fill has to be conducted for each specific machine, process, or container type. A recent survey of the BFS industry provides an excellent overview of the current practices in aseptic BFS technology, showing that the BFS process has a much lower frequency (about one-tenth) of contaminated media fills compared with conventional processes (7).

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here